Lenovo Announces New Innovations in Gaming, Software, Visuals, and Accessories for the Holidays
1.9.2023 07:20:00 EEST | Business Wire | Press release
Today, Lenovo announced several new products and solutions at its annual holiday product launch. The new additions to the portfolio – which include AI-tuned innovations in gaming, a groundbreaking 3D monitor, software solutions, versatile accessories, and more – are available to explore here.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831307965/en/
Lenovo Announces New Innovations in Gaming, Software, Visuals, and Accessories for the Holidays (Photo: Business Wire)
Gaming on the Go: Lenovo Legion™ Gaming Handheld Device and Accessories Untether PC Gaming
The new Lenovo Legion Go is the company’s first Windows gaming handheld device that gives gamers more freedom to game however—and wherever—they want. The Lenovo Legion Go is designed for gamers who will settle for nothing less than top-tier specs and visuals on their handheld device. Along with the new micro-OLED-equipped Lenovo Legion Glasses and new Lenovo Legion E510 7.1 RGB Gaming In-Ear Headphones, the debut of the Lenovo Legion Go is a marked expansion of the Lenovo Legion ecosystem of gaming devices, monitors, accessories, software, and services that empower gamers to immerse themselves in their games.
- The new Lenovo Legion Go brings Windows PC gaming power to a handheld mobile form factor, powered by AMD Ryzen™ Z1 Series processors that bring games to life on its 8.8-inch Lenovo PureSight Gaming Display.
- For gamers who want to take their Lenovo Legion Go portable gaming experience to the next level, the new Lenovo Legion Glasses leverage micro-OLED technology to provide a large screen viewing experience that fits in the pocket.
- For a truly immersive gaming experience, the new Lenovo Legion E510 7.1 RGB Gaming In-Ear Headphones offer hi-res 7.1 surround sound audio with a multifunction inline controller.
The King of Cool: Lenovo Legion 9i is the World’s First AI-Tuned Gaming Laptop with an Integrated Liquid-Cooling System1
The Lenovo Legion 9i (16”, 8) is the first top-of-the-line 16-inch gaming laptop in Lenovo Legion’s ecosystem—and in the world—with a self-contained liquid-cooling system1, designed for gamers and creators with heavy graphic workflow requirements who need a full development studio in their bag. The Lenovo Legion 9i leads the Lenovo Legion lineup that also includes the Lenovo Legion Pro series for competitive gamers and the Lenovo Legion Slim series for gamers who value agility, as well as Lenovo Legion displays and peripherals. Also announced today are the Lenovo Legion 16” Gaming Backpack GB700 and GB400, two backpack options that give gamers a choice between slim and lightweight agility or extra storage without sacrificing protection for their Lenovo Legion 9i (16”, 8) or any other laptops and accessories.
Transforming Digital Workspaces: New Devices and Software Power the Future of Hybrid Work
In addition to new gaming devices, Lenovo is unveiling new cutting-edge tech tools and essentials tailored to empower the dynamic, evolving needs of today's business end-users. Its new monitor, software, and accessories are not only designed to boost the capabilities of today’s remote and hybrid workforces, but also to address significant challenges faced by businesses as they digitize operations across departments. Lenovo research shows that managing a remote workforce and global teams remain central tasks for CIOs.2 That’s why the new offerings integrate impressive processing power, immersive 3D, and advanced security to create a unified, human-centered experience.
- For professional content creators who require immersive 3D visualization, the new ThinkVision™ 27 3D Monitor – a stunning 27-inch, glasses-free, 2D/3D compatible monitor – offers seamless 3D effects and real-time eye-tracking.
- The new Lenovo Wired VOIP Headset and Lenovo Wired ANC Headset Gen 2 are high-quality audio solutions for professionals in hybrid work environments, include an inline call control box, active noise cancellation with the latter, and compatibility with popular conferencing platforms.
- For remote work and to support sustainability efforts, the cloud-based Lenovo Device Manager will roll out enhanced new features that include a comprehensive AI-powered energy management solution that efficiently manages device fleets and optimizes power usage.
- To round out the new line-up are a selection of sophisticated and comfortable carry cases, the Lenovo ThinkPad Professional 16inch Backpack Gen 2, and the ThinkPad Professional 16inch and 14inch Topload Gen 2.
For specific details on all the new products and solutions, see the various releases linked below and the press kit on Lenovo StoryHub.
- The King of Cool: Lenovo Introduces the Legion 9i, the World’s First AI-Tuned Gaming Laptop with Integrated Liquid-Cooling System
- Gaming on the Go: Lenovo Unveils a New Legion Gaming Handheld Device and Accessories that Untether PC Gaming
- Transforming Digital Workspaces: Lenovo Unveils New Devices and Software to Power the Future of Hybrid Work
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
1Per an internal research conducted as of June 22, 2023, based on comparisons of gaming computers distributed by global PC manufacturers shipping > 1 million units worldwide annually, contained in a 16" panel size supported with a liquid cooling pump and does not have an external cooling attachment.
2 The Resilient CIO: Lenovo Global Study of CIOs 2023
LENOVO, LENOVO LEGION, and THINKVISION are trademarks of Lenovo. AMD and Ryzen are trademarks of Advanced Micro Devices. Inc. All other trademarks are the property of their respective owners. ©2023 Lenovo Group Limited
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831307965/en/
Contact information
Wendy Fung, wfung@lenovo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom